CRVO Logo

Cervomed Inc. (CRVO) Stock Forecast & Price Prediction

Live CRVO Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$2.33

+0.14 (6.39%)

12 Month Price Forecast For CRVO

$2.33
Current Price
$19.23M
Market Cap
8 Ratings
Buy 2
Hold 5
Sell 1
Wall St Analyst Ratings

Distance to CRVO Price Forecasts

+1,359.2%
To High Target of $34.00
+415.0%
To Median Target of $12.00
+71.7%
To Low Target of $4.00

CRVO Price Momentum

+5.4%
1 Week Change
+10.4%
1 Month Change
-86.1%
1 Year Change
-0.4%
Year-to-Date Change
-91.2%
From 52W High of $26.38
+29.4%
From 52W Low of $1.80

๐Ÿค” Considering Cervomed (CRVO)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 16, 2025 2:20 AM UTC

CRVO Analyst Ratings & Price Targets

Based on our analysis of 10 Wall Street analysts, CRVO has a neutral consensus with a median price target of $12.00 (ranging from $4.00 to $34.00). The overall analyst rating is Buy (6.3/10). Currently trading at $2.33, the median forecast implies a 415.0% upside. This outlook is supported by 2 Buy, 5 Hold, and 1 Sell ratings.

The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 1,359.2% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

CRVO Analyst Consensus

2
Buy
5
Hold
1
Sell

CRVO Price Target Range

Low
$4.00
Average
$12.00
High
$34.00
Current: $2.33

Latest CRVO Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for CRVO.

Date Firm Analyst Rating Change Price Target
Dec 17, 2024 HC Wainwright & Co. Raghuram Selvaraju Neutral Downgrade $0.00
Dec 11, 2024 Chardan Capital Daniil Gataulin Neutral Downgrade $0.00
Dec 11, 2024 Canaccord Genuity Sumant Kulkarni Buy Maintains $12.00
Dec 10, 2024 D. Boral Capital Jason Kolbert Hold Downgrade $0.00
Dec 10, 2024 Jones Trading Soumit Roy Hold Downgrade $0.00
Dec 5, 2024 Roth MKM Boobalan Pachaiyappan Buy Initiates $45.00
Dec 5, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Initiates $42.00
Nov 27, 2024 D. Boral Capital Jason Kolbert Buy Maintains $34.00
Nov 18, 2024 D. Boral Capital Jason Kolbert Buy Initiates $34.00
Nov 14, 2024 Chardan Capital Daniil Gataulin Buy Maintains $55.00
Sep 18, 2024 Chardan Capital Daniil Gataulin Buy Initiates $55.00
Jul 26, 2024 Morgan Stanley Jeffrey Hung Overweight Initiates $35.00
Jul 25, 2024 Canaccord Genuity Sumant Kulkarni Buy Maintains $65.00
Jul 8, 2024 Brookline Capital Tyler Bussian Buy Initiates $63.00
May 29, 2024 Jones Trading Soumit Roy Buy Initiates $70.00
Apr 8, 2024 Canaccord Genuity Sumant Kulkarni Buy Maintains $65.00
Feb 15, 2024 Canaccord Genuity Sumant Kulkarni Buy Initiates $50.00
Aug 16, 2022 HC Wainwright & Co. Swayampakula Ramakanth Buy Upgrade $9.50
Nov 25, 2020 H.C. Wainwright Buy Reiterates $0.00
Nov 17, 2020 HC Wainwright & Co. Neutral Downgrade $0.00

Stocks Similar to Cervomed Inc.

The following stocks are similar to Cervomed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Cervomed Inc. (CRVO) Financial Data

Cervomed Inc. has a market capitalization of $19.23M with a P/E ratio of 4.9x. The company generates $10.07M in trailing twelve-month revenue with a -118.7% profit margin.

Revenue growth is +27.1% quarter-over-quarter, while maintaining an operating margin of -278.2% and return on equity of -43.3%.

Valuation Metrics

Market Cap $19.23M
Enterprise Value $-27,425,686
P/E Ratio 4.9x
PEG Ratio -0.9x
Price/Sales 1.9x

Growth & Margins

Revenue Growth (YoY) +27.1%
Gross Margin N/A
Operating Margin -278.2%
Net Margin -118.7%
EPS Growth N/A

Financial Health

Cash/Price Ratio +242.6%
Current Ratio 15.0x
Debt/Equity 0.0x
ROE -43.3%
ROA -26.0%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Cervomed Inc. logo

Cervomed Inc. (CRVO) Company Overview

About Cervomed Inc.

What They Do

Develops treatments for age-related neurologic disorders.

Business Model

CervoMed Inc. focuses on developing and commercializing innovative therapeutics targeting age-related neurological conditions. The company generates revenue through the advancement of its drug candidates, such as neflamapimod, which aims to address significant unmet medical needs in dementia and related disorders.

Additional Information

Founded in 2010 and based in Boston, Massachusetts, CervoMed is actively engaged in preclinical trials for its EIP200 candidate, indicating a strong pipeline for future growth. The company's focus on age-related neurological disorders positions it in a growing market driven by an aging population.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

8

CEO

Dr. John J. Alam M.D.

Country

United States

IPO Year

2023

Cervomed Inc. (CRVO) Latest News & Analysis

CRVO stock latest news image
Quick Summary

CervoMed Inc. (NASDAQ: CRVO) will present topline results from its Phase 2b RewinD-LB study on neflamapimod for dementia with Lewy bodies at the ILBDC on January 31, 2025.

Why It Matters

The presentation of Phase 2b results for CervoMed's neflamapimod at a major conference could significantly impact stock performance, influencing investor sentiment around its potential in treating DLB.

Source: GlobeNewsWire
Market Sentiment: Neutral
CRVO stock latest news image
Quick Summary

CervoMed's experimental drug for a common degenerative brain disease failed to meet primary and secondary goals in a mid-stage clinical trial, according to their announcement on Tuesday.

Why It Matters

CervoMed's failed trial may lead to reduced investor confidence, potential stock price decline, and concerns over future drug development and funding prospects.

Source: Reuters
Market Sentiment: Negative
CRVO stock latest news image
Quick Summary

CervoMed Inc. (CRVO) stock declined following the release of topline data from its Phase 2b clinical trial of neflamapimod for dementia with Lewy bodies.

Why It Matters

CervoMed's stock decline reflects investor concern over trial results for neflamapimod, potentially impacting future revenue and market confidence in the company's pipeline.

Source: Benzinga
Market Sentiment: Negative
CRVO stock latest news image
Quick Summary

CervoMed Inc.'s stock dropped significantly after the company announced that a midstage trial for its DLB treatment did not achieve its primary objectives.

Why It Matters

CervoMed's stock drop signals negative investor sentiment due to failed clinical trial results, raising concerns about the company's future prospects and financial health.

Source: Market Watch
Market Sentiment: Negative
CRVO stock latest news image
Quick Summary

Neflamapimod failed to show statistically significant effects compared to placebo on primary and secondary endpoints after 16 weeks of study.

Why It Matters

Neflamapimod's failure in clinical trials raises concerns about its market viability, potentially impacting the company's stock and investor confidence in its drug pipeline.

Source: GlobeNewsWire
Market Sentiment: Neutral
CRVO stock latest news image
Quick Summary

CervoMed Inc. (NASDAQ: CRVO) has granted equity awards to attract two new employees, indicating its commitment to expanding its team in age-related neurologic disorder treatments.

Why It Matters

CervoMed's equity awards signal confidence in growth and potential, impacting investor sentiment and stock performance as the company expands its talent for drug development.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About CRVO Stock

What is Cervomed Inc.'s (CRVO) stock forecast for 2025?

Based on our analysis of 10 Wall Street analysts, Cervomed Inc. (CRVO) has a median price target of $12.00. The highest price target is $34.00 and the lowest is $4.00.

Is CRVO stock a good investment in 2025?

According to current analyst ratings, CRVO has 2 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $2.33. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for CRVO stock?

Wall Street analysts predict CRVO stock could reach $12.00 in the next 12 months. This represents a 415.0% increase from the current price of $2.33. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Cervomed Inc.'s business model?

CervoMed Inc. focuses on developing and commercializing innovative therapeutics targeting age-related neurological conditions. The company generates revenue through the advancement of its drug candidates, such as neflamapimod, which aims to address significant unmet medical needs in dementia and related disorders.

What is the highest forecasted price for CRVO Cervomed Inc.?

The highest price target for CRVO is $34.00 from Jason Kolbert at D. Boral Capital, which represents a 1,359.2% increase from the current price of $2.33.

What is the lowest forecasted price for CRVO Cervomed Inc.?

The lowest price target for CRVO is $4.00 from at , which represents a 71.7% increase from the current price of $2.33.

What is the overall CRVO consensus from analysts for Cervomed Inc.?

The overall analyst consensus for CRVO is neutral. Out of 10 Wall Street analysts, 2 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $12.00.

How accurate are CRVO stock price projections?

Stock price projections, including those for Cervomed Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.